CA Patent

CA3214552A1 — Cd71 binding fibronectin type iii domains

Assigned to Aro Biotherapeutics Co · Expires 2022-10-20 · 4y expired

What this patent protects

The present disclosure relates to polypeptides, such as fibronectin type 111 (FN3) domains that can bind CD71, their conjugates, isolated nucleotides encoding the molecules, vectors, host-cells, as well as methods of making and using the same. In some embodiments, the FN3 domains…

USPTO Abstract

The present disclosure relates to polypeptides, such as fibronectin type 111 (FN3) domains that can bind CD71, their conjugates, isolated nucleotides encoding the molecules, vectors, host-cells, as well as methods of making and using the same. In some embodiments, the FN3 domains are isolated. In some embodiments, the FN3 domains are recombinant. In some embodiments, the FN3 domains are non-naturally occurring.

Drugs covered by this patent

Patent Metadata

Patent number
CA3214552A1
Jurisdiction
CA
Classification
—
Expires
2022-10-20
Drug substance claim
No
Drug product claim
No
Assignee
Aro Biotherapeutics Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.